首页> 外国专利> Oligomeric nucleic acid molecules and their use for the treatment of acute intermittent porphyria

Oligomeric nucleic acid molecules and their use for the treatment of acute intermittent porphyria

机译:寡聚核酸分子及其用于治疗急性间歇性卟啉症的用途

摘要

The present invention relates to compositions of small activating nucleic acid molecules that increase the expression of HMBS genes and their use. The small activating nucleic acid molecule may be a double-stranded or single-stranded RNA molecule targeting the promoter region of the HMBS gene. The first nucleic acid strand and the second nucleic acid strand each contain a region of complementarity, and the region of complementarity may form a double-stranded nucleic acid structure capable of promoting expression of the HMBS gene. The first nucleic acid strand or the second nucleic acid strand independently has a length of 16 to 35 nucleotides. The 3' end of the two oligonucleotide strands may have an overhang of 0 to 6 nucleotides in length. A small activating nucleic acid molecule for the HMBS gene can be used to up-regulate mRNA and protein expression of the HMBS gene and promote its enzymatic activity.
机译:本发明涉及小活化核酸分子的组成,其增加了HMBS基因的表达及其使用。 小激活核酸分子可以是靶向HMBS基因的启动子区的双链或单链RNA分子。 第一核酸链和第二核酸链各自含有互补性区域,并且互补性的区域可以形成能够促进HMBS基因表达的双链核酸结构。 第一核酸链或第二核酸链独立地具有16至35个核苷酸的长度。 两个寡核苷酸链的3'末端可以具有长度为0至6个核苷酸的突起。 用于HMBS基因的小激活核酸分子可用于上调HMBS基因的mRNA和蛋白表达并促进其酶活性。

著录项

  • 公开/公告号KR20220002896A

    专利类型

  • 公开/公告日2022-01-07

    原文格式PDF

  • 申请/专利权人 락티젠 세러퓨틱스;

    申请/专利号KR1020217033428

  • 发明设计人 리 롱청;강 무림;

    申请日2020-04-29

  • 分类号C12N15/113;A61K31/713;A61P3;A61P7;C12N15/85;C12N15/90;C12N9/10;

  • 国家 KR

  • 入库时间 2022-08-24 23:26:23

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号